The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Design Therapeutics, Inc. (NASDAQ:DSGN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. A caller asked for Cramer’s thoughts on the company, and here’s what he had to say:

Pure spec, pure spec. Understand, you can lose everything, or you can double on that one. I don’t know which it’s going to be. That’s the problem.

A stock market graph. Photo by energepic.com

Design Therapeutics, Inc. (NASDAQ:DSGN) is a clinical-stage biopharmaceutical company that develops small-molecule drugs to treat inherited genetic diseases caused by nucleotide repeat expansion. The company uses its proprietary platform, GeneTAC, to create potential treatments for conditions such as Friedreich’s Ataxia, Huntington’s Disease, and other progressive neuromuscular and neurodegenerative disorders.

While we acknowledge the potential of DSGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.